{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:57:32Z","timestamp":1793757452998,"version":"4.6.1"},"reference-count":188,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bcp.2025.117313","type":"journal-article","created":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T14:21:04Z","timestamp":1757254864000},"page":"117313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"P2","title":["DNA methylation as an oncogenic driver in breast cancer: Therapeutic targeting via epigenetic reprogramming of DNA methyltransferases"],"prefix":"10.1016","volume":"242","author":[{"given":"Sweta","family":"Kundu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sampriti","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suparna","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0331-0314","authenticated-orcid":false,"given":"Avik","family":"Acharya Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2025.117313_b0005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The Hallmarks of Cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2025.117313_b0010","doi-asserted-by":"crossref","unstructured":"G.N. Hortobagyi J. De La Garza Salazar K. Pritchard D. Amadori R. Haidinger C.A. Hudis H. Khaled M.-C. Liu M. Martin M. Namer J.A. O\u2019Shaughnessy Z.Z. Shen K.S. Albain The Global Breast Cancer Burden: Variations in Epidemiology and Survival, Clinical Breast Cancer 6 2005 10.3816\/CBC.2005.n.043 391 401.","DOI":"10.3816\/CBC.2005.n.043"},{"key":"10.1016\/j.bcp.2025.117313_b0015","unstructured":"Cancer Today, (n.d.). https:\/\/gco.iarc.who.int\/today\/."},{"key":"10.1016\/j.bcp.2025.117313_b0020","doi-asserted-by":"crossref","first-page":"955","DOI":"10.4161\/cbt.10.10.13879","article-title":"Histological, molecular and functional subtypes of breast cancers","volume":"10","author":"Malhotra","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.bcp.2025.117313_b0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41523-025-00723-0","article-title":"The Breast Cancer Classifier refines molecular breast cancer classification to delineate the HER2-low subtype","volume":"11","author":"Turova","year":"2025","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.bcp.2025.117313_b0030","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13058-025-02057-y","article-title":"DNA methylation patterns in breast cancer, paired benign tissue from ipsilateral and contralateral breast, and healthy controls","volume":"27","author":"Dennis","year":"2025","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bcp.2025.117313_b0035","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.celrep.2018.09.082","article-title":"Pan-Cancer Landscape of Aberrant DNA Methylation across Human Tumors","volume":"25","author":"Saghafinia","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.bcp.2025.117313_b0040","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ijc.29684","article-title":"Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes: Prognostic value of methylation in breast cancer subtypes","volume":"138","author":"Gy\u0151rffy","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bcp.2025.117313_b0045","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nrg.2016.93","article-title":"Targeting the cancer epigenome for therapy","volume":"17","author":"Jones","year":"2016","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.bcp.2025.117313_b0050","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.916725","article-title":"DNMT3A and DNMT3B in Breast Tumorigenesis and potential Therapy","volume":"10","author":"Man","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bcp.2025.117313_b0055","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature17676","article-title":"Landscape of somatic mutations in 560 breast cancer whole-genome sequences","volume":"534","author":"Nik-Zainal","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2025.117313_b0060","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nm1087","article-title":"Cancer genes and the pathways they control","volume":"10","author":"Vogelstein","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2025.117313_b0065","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/s41416-020-0992-6","article-title":"Progesterone receptor membrane component 1 promotes the growth of breast cancers by altering the phosphoproteome and augmenting EGFR\/PI3K\/AKT signalling","volume":"123","author":"Pedroza","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcp.2025.117313_b0070","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41586-019-1411-0","article-title":"Advances in epigenetics link genetics to the environment and disease","volume":"571","author":"Cavalli","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2025.117313_b0075","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1039\/C6CS00599C","article-title":"Epigenetic modification of nucleic acids: from basic studies to medical applications","volume":"46","author":"Chen","year":"2017","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.bcp.2025.117313_b0080","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/ng1068","article-title":"DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells","volume":"33","author":"Robert","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcp.2025.117313_b0085","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1038\/ncponc0354","article-title":"DNA methylation and gene silencing in cancer","volume":"2","author":"Baylin","year":"2005","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bcp.2025.117313_b0090","first-page":"758","article-title":"Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias","volume":"8","author":"Corradini","year":"1994","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2025.117313_b0095","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/30764","article-title":"Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex","volume":"393","author":"Nan","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2025.117313_b0100","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.1093\/nar\/29.22.4598","article-title":"Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methylation, MeCP2 binding and acetylation","volume":"29","author":"Nguyen","year":"2001","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bcp.2025.117313_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.genet.34.1.1","article-title":"CHASING THE CANCER DEMON","volume":"34","author":"Knudson","year":"2000","journal-title":"Annu. Rev. Genet."},{"key":"10.1016\/j.bcp.2025.117313_b0110","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/path.1297","article-title":"Concomitant expression of p16INK4a and p14ARF in primary breast cancer and analysis of inactivation mechanisms","volume":"199","author":"Silva","year":"2003","journal-title":"J. Pathol."},{"key":"10.1016\/j.bcp.2025.117313_b0115","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s12885-019-5403-0","article-title":"Roadmap of DNA methylation in breast cancer identifies novel prognostic biomarkers","volume":"19","author":"De Almeida","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bcp.2025.117313_b0120","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/jnci\/92.7.564","article-title":"Promoter Hypermethylation and BRCA1 Inactivation in sporadic Breast and Ovarian Tumors","volume":"92","author":"Esteller","year":"2000","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/j.bcp.2025.117313_b0125","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1158\/0008-5472.CAN-03-3341","article-title":"Quantitative Multiplex Methylation-specific PCR Assay for the Detection of Promoter Hypermethylation in Multiple Genes in Breast Cancer","volume":"64","author":"Fackler","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2025.117313_b0130","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nrc3486","article-title":"Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host","volume":"13","author":"Timp","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2025.117313_b0135","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1038\/s41467-019-09937-w","article-title":"Chromatin dysregulation and DNA methylation at transcription start sites associated with transcriptional repression in cancers","volume":"10","author":"Ando","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2025.117313_b0140","first-page":"589","article-title":"Histone modifications and cancer: biomarkers of prognosis?","volume":"2","author":"Chervona","year":"2012","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bcp.2025.117313_b0145","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1038\/emm.2017.11","article-title":"Writing, erasing and reading histone lysine methylations","volume":"49","author":"Hyun","year":"2017","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bcp.2025.117313_b0150","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41594-019-0298-7","article-title":"Histone lysine methyltransferases in biology and disease","volume":"26","author":"Husmann","year":"2019","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bcp.2025.117313_b0155","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.molcel.2012.11.006","article-title":"Histone Lysine Methylation Dynamics: Establishment, Regulation, and Biological Impact","volume":"48","author":"Black","year":"2012","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcp.2025.117313_b0160","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/ng1531","article-title":"Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer","volume":"37","author":"Fraga","year":"2005","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcp.2025.117313_b0165","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1158\/0008-5472.CAN-08-3907","article-title":"Global Histone modifications in Breast Cancer Correlate with Tumor Phenotypes, Prognostic Factors, and Patient Outcome","volume":"69","author":"Elsheikh","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2025.117313_b0170","first-page":"1207","article-title":"The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma, Intl","volume":"122","author":"Pfister","year":"2008","journal-title":"J. Cancer"},{"key":"10.1016\/j.bcp.2025.117313_b0175","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1083\/jcb.200108049","article-title":"BRCA1-induced large-scale chromatin unfolding and allele-specific effects of cancer-predisposing mutations","volume":"155","author":"Ye","year":"2001","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bcp.2025.117313_b0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017830","article-title":"Histone Demethylase JMJD2B Functions as a Co-factor of Estrogen Receptor in Breast Cancer Proliferation and Mammary Gland Development","volume":"6","author":"Kawazu","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2025.117313_b0185","doi-asserted-by":"crossref","first-page":"323","DOI":"10.4048\/jbc.2014.17.4.323","article-title":"Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast","volume":"17","author":"Seo","year":"2014","journal-title":"J. Breast Cancer"},{"key":"10.1016\/j.bcp.2025.117313_b0190","first-page":"1213","article-title":"HDAC2 overexpression correlates with aggressive clinicopathological features and DNA-damage response pathway of breast cancer","volume":"7","author":"Shan","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bcp.2025.117313_b0195","first-page":"971","article-title":"Trichostatin a is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo","volume":"7","author":"Vigushin","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2025.117313_b0200","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.3892\/ijo.2015.3213","article-title":"Valproic acid inhibits proliferation of HER2-expressing breast cancer cells by inducing cell cycle arrest and apoptosis through Hsp70 acetylation","volume":"47","author":"Mawatari","year":"2015","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bcp.2025.117313_b0205","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41568-020-0253-2","article-title":"Role of RNA modifications in cancer","volume":"20","author":"Barbieri","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2025.117313_b0210","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/nrc3166","article-title":"MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy","volume":"11","author":"Kasinski","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2025.117313_b0215","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1186\/s12864-019-5887-7","article-title":"Refinement of breast cancer molecular classification by miRNA expression profiles","volume":"20","author":"S\u00f8kilde","year":"2019","journal-title":"BMC Genomics"},{"key":"10.1016\/j.bcp.2025.117313_b0220","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1158\/1078-0432.CCR-12-3401","article-title":"Identification of Circulating MicroRNA Signatures for Breast Cancer Detection","volume":"19","author":"Chan","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2025.117313_b0225","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13058-018-1090-z","article-title":"Molecular and epigenetic profiles of BRCA1-like hormone-receptor-positive breast tumors identified with development and application of a copy-number-based classifier","volume":"21","author":"Chen","year":"2019","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bcp.2025.117313_b0230","doi-asserted-by":"crossref","first-page":"6195","DOI":"10.1158\/0008-5472.CAN-11-1630","article-title":"Genome-wide Methylation Analysis Identifies Genes specific to Breast Cancer Hormone Receptor Status and risk of Recurrence","volume":"71","author":"Fackler","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2025.117313_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102642","article-title":"ESR1 mutations in HR+\/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing","author":"Venetis","year":"2023","journal-title":"Cancer Treatment Reviews 121"},{"key":"10.1016\/j.bcp.2025.117313_b0240","doi-asserted-by":"crossref","unstructured":"Y. Oubaddou, M. Oukabli, S. Fenniche, A. Elktaibi, M.R. Elochi, A. Al Bouzidi, Z. Qmichou, N. Dakka, C. Diorio, A. Richter, Y. Bakri, R. Ameziane El Hassani, Brca1 promoter hypermethylation in malignant breast tumors and in the histologically normal adjacent tissues to the tumors: exploring its potential as a biomarker and its clinical significance in a translational approach, Genes (Basel) 14 (2023) 1680. https:\/\/doi.org\/10.3390\/genes14091680.","DOI":"10.3390\/genes14091680"},{"key":"10.1016\/j.bcp.2025.117313_b0245","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10549-020-05647-w","article-title":"BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib\/eribulin combination therapy","volume":"181","author":"Kawachi","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bcp.2025.117313_b0250","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13148-024-01787-8","article-title":"BRCA1 & BRCA2 methylation as a prognostic and predictive biomarker in cancer: Implementation in liquid biopsy in the era of precision medicine","volume":"16","author":"Panagopoulou","year":"2024","journal-title":"Clin Epigenet"},{"key":"10.1016\/j.bcp.2025.117313_b0255","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s10549-013-2774-9","article-title":"Promoter methylation of BRCA1 in the prognosis of breast cancer: a meta-analysis","volume":"142","author":"Wu","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bcp.2025.117313_b0260","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1111\/j.1349-7006.2009.01225.x","article-title":"BRCA1 promoter methylation associated with poor survival in chinese patients with sporadic breast cancer","volume":"100","author":"Chen","year":"2009","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bcp.2025.117313_b0265","article-title":"The association between the methylation frequency of BRCA1\/2 gene promoter and occurrence and prognosis of breast carcinoma: a meta-analysis","volume":"99","author":"Li","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.bcp.2025.117313_b0270","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.1002\/mco2.403","article-title":"Methylation of ESR1 promoter induced by SNAI2\u2013DNMT3B complex promotes epithelial\u2013mesenchymal transition and correlates with poor prognosis in ER\u03b1\u2010positive breast cancers","volume":"4","author":"Li","year":"2023","journal-title":"MedComm"},{"key":"10.1016\/j.bcp.2025.117313_b0275","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2200022119","article-title":"NOS2 and S -nitrosothiol signaling induces DNA hypomethylation and LINE-1 retrotransposon expression","volume":"119","author":"Switzer","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bcp.2025.117313_b0280","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1126\/science.1210597","article-title":"Tet Proteins can Convert 5-Methylcytosine to 5-Formylcytosine and 5-Carboxylcytosine","volume":"333","author":"Ito","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.bcp.2025.117313_b0285","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.1158\/0008-5472.CAN-17-2082","article-title":"TET1-Mediated Hypomethylation Activates Oncogenic Signaling in Triple-negative Breast Cancer","volume":"78","author":"Good","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2025.117313_b0290","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.neo.2020.11.002","article-title":"Estrogen-induced hypomethylation and overexpression of YAP1 facilitate breast cancer cell growth and survival","volume":"23","author":"Muhammad","year":"2021","journal-title":"Neoplasia"},{"key":"10.1016\/j.bcp.2025.117313_b0295","doi-asserted-by":"crossref","first-page":"6031","DOI":"10.3390\/cancers13236031","article-title":"Epigenetic Dysregulation of KCNK9 Imprinting and Triple-negative Breast Cancer","volume":"13","author":"Skaar","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bcp.2025.117313_b0300","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.236125","article-title":"5-Aza-2\u2032-deoxycytidine advances the epithelial\u2013mesenchymal transition of breast cancer cells by demethylating Sipa1 promoter-proximal elements","author":"Lu","year":"2020","journal-title":"Journal of Cell Science 133"},{"key":"10.1016\/j.bcp.2025.117313_b0305","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3390\/ijms21030903","article-title":"ADAM12 is a potential Therapeutic Target Regulated by Hypomethylation in Triple-negative Breast Cancer","volume":"21","author":"Mendaza","year":"2020","journal-title":"IJMS"},{"key":"10.1016\/j.bcp.2025.117313_b0310","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.3892\/ol.2020.11745","article-title":"Tumor DNA hypomethylation of LINE\u20131 is associated with low tumor grade of breast cancer in Tunisian patients","volume":"20","author":"Zeggar","year":"2020","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bcp.2025.117313_b0315","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/1471-2407-9-217","article-title":"Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer","volume":"9","author":"Veeck","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bcp.2025.117313_b0320","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/carcin\/bgi379","article-title":"Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer","volume":"27","author":"Ai","year":"2006","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bcp.2025.117313_b0325","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s10238-019-00583-6","article-title":"Impact of estrogen receptor \u03b1 on the tamoxifen response and prognosis in luminal-A-like and luminal-B-like breast cancer","volume":"19","author":"Babyshkina","year":"2019","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.bcp.2025.117313_b0330","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1476-4598-7-15","article-title":"DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines","volume":"7","author":"Roll","year":"2008","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bcp.2025.117313_b0335","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/1476-4598-9-274","article-title":"Synergistic epigenetic reactivation of estrogen receptor-\u03b1 (ER\u03b1) by combined green tea polyphenol and histone deacetylase inhibitor in ER\u03b1-negative breast cancer cells","volume":"9","author":"Li","year":"2010","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bcp.2025.117313_b0340","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1038\/s41598-022-08210-3","article-title":"Clinical associations of ESR2 (estrogen receptor beta) expression across thousands of primary breast tumors","volume":"12","author":"Dalal","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2025.117313_b0345","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/jcmm.12099","article-title":"Epigenetic silencing of the WNT antagonist Dickkopf 3 disrupts normal Wnt\/\u03b2\u2010catenin signalling and apoptosis regulation in breast cancer cells","volume":"17","author":"Xiang","year":"2013","journal-title":"J Cellular Molecular Medi"},{"key":"10.1016\/j.bcp.2025.117313_b0350","doi-asserted-by":"crossref","first-page":"5105","DOI":"10.1128\/MCB.00162-07","article-title":"Integration of Estrogen and Wnt Signaling Circuits by the Polycomb Group Protein EZH2 in Breast Cancer Cells","volume":"27","author":"Shi","year":"2007","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bcp.2025.117313_b0355","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.3892\/ol.2016.4274","article-title":"CDH1 promoter methylation correlates with decreased gene expression and poor prognosis in patients with breast cancer","volume":"11","author":"Liu","year":"2016","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bcp.2025.117313_b0360","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3892\/or.2020.7860","article-title":"Phenethyl isothiocyanate reduces breast cancer stem cell-like properties by epigenetic reactivation of CDH1","volume":"45","author":"Zhang","year":"2020","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bcp.2025.117313_b0365","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00487","article-title":"Functional Role of G9a Histone Methyltransferase in Cancer","volume":"6","author":"Casciello","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2025.117313_b0370","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1172\/JCI57349","article-title":"G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer","volume":"122","author":"Dong","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2025.117313_b0375","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrg1655","article-title":"DNA methylation and human disease","volume":"6","author":"Robertson","year":"2005","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.bcp.2025.117313_b0380","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2217\/epi.14.80","article-title":"Genetic Alterations of DNA Methylation Machinery in Human Diseases","volume":"7","author":"Hamidi","year":"2015","journal-title":"Epigenomics"},{"key":"10.1016\/j.bcp.2025.117313_b0385","doi-asserted-by":"crossref","unstructured":"T. Chen, E. Li, Structure and Function of Eukaryotic DNA Methyltransferases, in: Current Topics in Developmental Biology, Elsevier, 2004: pp. 55\u201389. https:\/\/doi.org\/10.1016\/S0070-2153(04)60003-2.","DOI":"10.1016\/S0070-2153(04)60003-2"},{"key":"10.1016\/j.bcp.2025.117313_b0390","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0092-8674(00)81656-6","article-title":"DNA Methyltransferases Dnmt3a and Dnmt3b are Essential for De Novo Methylation and Mammalian Development","volume":"99","author":"Okano","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2025.117313_b0395","first-page":"271","article-title":"MC3 Working Group","volume":"6","author":"Ellrott","year":"2018","journal-title":"Cancer Genome Atlas Research Network, Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines, Cell Syst"},{"key":"10.1016\/j.bcp.2025.117313_b0400","doi-asserted-by":"crossref","unstructured":"K.A. Hoadley, C. Yau, T. Hinoue, D.M. Wolf, A.J. Lazar, E. Drill, R. Shen, A.M. Taylor, A.D. Cherniack, V. Thorsson, R. Akbani, R. Bowlby, C.K. Wong, M. Wiznerowicz, F. Sanchez-Vega, A.G. Robertson, B.G. Schneider, M.S. Lawrence, H. Noushmehr, T.M. Malta, Cancer Genome Atlas Network, J.M. Stuart, C.C. Benz, P.W. Laird, Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer, Cell 173 (2018) 291-304.e6. https:\/\/doi.org\/10.1016\/j.cell.2018.03.022.","DOI":"10.1016\/j.cell.2018.03.022"},{"key":"10.1016\/j.bcp.2025.117313_b0405","doi-asserted-by":"crossref","unstructured":"F. Sanchez-Vega, M. Mina, J. Armenia, W.K. Chatila, A. Luna, K.C. La, S. Dimitriadoy, D.L. Liu, H.S. Kantheti, S. Saghafinia, D. Chakravarty, F. Daian, Q. Gao, M.H. Bailey, W.-W. Liang, S.M. Foltz, I. Shmulevich, L. Ding, Z. Heins, A. Ochoa, B. Gross, J. Gao, H. Zhang, R. Kundra, C. Kandoth, I. Bahceci, L. Dervishi, U. Dogrusoz, W. Zhou, H. Shen, P.W. Laird, G.P. Way, C.S. Greene, H. Liang, Y. Xiao, C. Wang, A. Iavarone, A.H. Berger, T.G. Bivona, A.J. Lazar, G.D. Hammer, T. Giordano, L.N. Kwong, G. McArthur, C. Huang, A.D. Tward, M.J. Frederick, F. McCormick, M. Meyerson, Cancer Genome Atlas Research Network, E.M. Van Allen, A.D. Cherniack, G. Ciriello, C. Sander, N. Schultz, Oncogenic Signaling Pathways in The Cancer Genome Atlas, Cell 173 (2018) 321-337.e10. https:\/\/doi.org\/10.1016\/j.cell.2018.03.035.","DOI":"10.1016\/j.cell.2018.03.035"},{"key":"10.1016\/j.bcp.2025.117313_b0410","first-page":"400","article-title":"Cancer Genome Atlas Research Network, H","volume":"173","author":"Liu","year":"2018","journal-title":"Hu, an Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics, Cell"},{"key":"10.1016\/j.bcp.2025.117313_b0415","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1126\/science.1195380","article-title":"Structure of DNMT1-DNA complex reveals a Role for Autoinhibition in Maintenance DNA Methylation","volume":"331","author":"Song","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.bcp.2025.117313_b0420","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1038\/s41467-020-17109-4","article-title":"Comprehensive structure-function characterization of DNMT3B and DNMT3A reveals distinctive de novo DNA methylation mechanisms","volume":"11","author":"Gao","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2025.117313_b0425","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1010855","article-title":"The DNMT3A ADD domain is required for efficient de novo DNA methylation and maternal imprinting in mouse oocytes","volume":"19","author":"Uehara","year":"2023","journal-title":"PLoS Genet."},{"key":"10.1016\/j.bcp.2025.117313_b0430","unstructured":"CDD Conserved Protein Domain Family: PWWP_DNMT3, (n.d.). https:\/\/www.ncbi.nlm.nih.gov\/Structure\/cdd\/cd05835 (accessed August 26, 2025)."},{"key":"10.1016\/j.bcp.2025.117313_b0435","doi-asserted-by":"crossref","first-page":"12476","DOI":"10.1093\/nar\/gkad972","article-title":"Structural basis for the allosteric regulation and dynamic assembly of DNMT3B","volume":"51","author":"Lu","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bcp.2025.117313_b0440","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1021\/acs.biochem.6b00964","article-title":"Dnmt3b Methylates DNA by a Noncooperative Mechanism, and its activity is Unaffected by Manipulations at the Predicted Dimer Interface","volume":"57","author":"Norvil","year":"2018","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2025.117313_b0445","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13072-024-00566-2","article-title":"Tissue-specific roles of de novo DNA methyltransferases","volume":"18","author":"T\u00f3th","year":"2025","journal-title":"Epigenetics Chromatin"},{"key":"10.1016\/j.bcp.2025.117313_b0450","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1172\/JCI97924","article-title":"DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine","volume":"128","author":"Yu","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bcp.2025.117313_b0455","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ctrv.2017.01.004","article-title":"Clinical and biological effects of demethylating agents on solid tumours \u2013 a systematic review","volume":"54","author":"Linnekamp","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bcp.2025.117313_b0460","first-page":"8","article-title":"Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine, Intl","volume":"123","author":"Stresemann","year":"2008","journal-title":"J. Cancer"},{"key":"10.1016\/j.bcp.2025.117313_b0465","doi-asserted-by":"crossref","first-page":"6993","DOI":"10.1073\/pnas.81.22.6993","article-title":"Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine","volume":"81","author":"Santi","year":"1984","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bcp.2025.117313_b0470","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1158\/1078-0432.CCR-06-2762","article-title":"Effect of Cytarabine and Decitabine in Combination in Human Leukemic Cell Lines","volume":"13","author":"Qin","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2025.117313_b0475","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0092-8674(80)90237-8","article-title":"Cellular differentiation, cytidine analogs and DNA methylation","volume":"20","author":"Jones","year":"1980","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2025.117313_b0480","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1634\/theoncologist.10-3-176","article-title":"FDA Drug Approval Summary: Azacitidine (5-azacytidine, VidazaTM) for Injectable Suspension","volume":"10","author":"Kaminskas","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.bcp.2025.117313_b0485","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0163-7258(85)90053-1","article-title":"Molecular, cellular and animal pharmacology of 5-AZA-2\u2032-deoxycytidine","volume":"30","author":"Momparler","year":"1985","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2025.117313_b0490","first-page":"55","article-title":"Phase II study of 5-azacytidine in solid tumors","volume":"61","author":"Weiss","year":"1977","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/j.bcp.2025.117313_b0495","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1042\/BST0320910","article-title":"Zebularine: a new drug for epigenetic therapy","volume":"32","author":"Yoo","year":"2004","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.bcp.2025.117313_b0500","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1080\/13543784.2019.1667331","article-title":"Guadecitabine (SGI-110): an investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia","volume":"28","author":"Daher-Reyes","year":"2019","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.bcp.2025.117313_b0505","doi-asserted-by":"crossref","first-page":"6293","DOI":"10.1074\/jbc.M114.594671","article-title":"New Insights on the Mechanism of Quinoline-based DNA Methyltransferase Inhibitors","volume":"290","author":"Gros","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2025.117313_b0510","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/biom7010003","article-title":"DNA Methylation Targeting: the DNMT\/HMT Crosstalk Challenge","volume":"7","author":"Castillo-Aguilera","year":"2017","journal-title":"Biomolecules"},{"key":"10.1016\/j.bcp.2025.117313_b0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107328","article-title":"Non-nucleoside inhibitors of DNMT1 and DNMT3 for targeted cancer therapy","volume":"207","author":"Chen","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2025.117313_b0520","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1021\/jm500843d","article-title":"Targeting DNA methylation with small molecules: what\u2019s next?","volume":"58","author":"Erdmann","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117313_b0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114646","article-title":"Discovery of novel non-nucleoside inhibitors with high potency and selectivity for DNA methyltransferase 3A","volume":"242","author":"Yu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117313_b0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.127908","article-title":"A novel class of selective non-nucleoside inhibitors of human DNA methyltransferase 3A","volume":"40","author":"Huang","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2025.117313_b0535","first-page":"5799","article-title":"DNMTs inhibitor SGI-1027 induces apoptosis in Huh7 human hepatocellular carcinoma cells","volume":"16","author":"Sun","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bcp.2025.117313_b0540","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41419-020-02934-8","article-title":"Combined inhibition of JAK1\/2 and DNMT1 by newly identified small-molecule compounds synergistically suppresses the survival and proliferation of cervical cancer cells","volume":"11","author":"She","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2025.117313_b0545","first-page":"993","article-title":"DNA methylation enzyme inhibitor RG108 suppresses the radioresistance of esophageal cancer","volume":"39","author":"Ou","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bcp.2025.117313_b0550","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.2174\/13816128113199990516","article-title":"Anti-tumoral effect of the non-nucleoside DNMT inhibitor RG108 in human prostate cancer cells","volume":"20","author":"Gra\u00e7a","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bcp.2025.117313_b0555","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1158\/1535-7163.MCT-10-0609","article-title":"Nanaomycin a selectively inhibits DNMT3B and reactivates silenced tumor suppressor genes in human cancer cells","volume":"9","author":"Kuck","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2025.117313_b0560","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1089\/scd.2017.0251","article-title":"Nanaomycin a Treatment Promotes Hepatoblast Differentiation from Human iPS Cells","volume":"27","author":"Nakamae","year":"2018","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.bcp.2025.117313_b0565","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s13402-022-00717-1","article-title":"Comparative oncology reveals DNMT3B as a molecular vulnerability in undifferentiated pleomorphic sarcoma","volume":"45","author":"Fuller","year":"2022","journal-title":"Cell. Oncol. (Dordr.)"},{"key":"10.1016\/j.bcp.2025.117313_b0570","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1021\/acschembio.3c00065","article-title":"Mechanistic Insights into Harmine-Mediated Inhibition of Human DNA Methyltransferases and Prostate Cancer Cell Growth","volume":"18","author":"Cho","year":"2023","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bcp.2025.117313_b0575","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.3390\/molecules24162899","article-title":"The Inhibitory effect of (\u2212)-Epigallocatechin-3-Gallate on Breast Cancer Progression via reducing SCUBE2 Methylation and DNMT activity","volume":"24","author":"Sheng","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2025.117313_b0580","first-page":"789","article-title":"Epigallocatechin Gallate (EGCG), an active Phenolic compound of Green Tea","volume":"11","author":"Agarwal","year":"2023","journal-title":"Inhibits Tumor Growth of Head and Neck Cancer Cells by Targeting DNA Hypermethylation, Biomedicines"},{"key":"10.1016\/j.bcp.2025.117313_b0585","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1371\/journal.pone.0000098","article-title":"A Proof-Of-Principle Study of Epigenetic Therapy added to Neoadjuvant Doxorubicin Cyclophosphamide for locally Advanced Breast Cancer","volume":"1","author":"Arce","year":"2006","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2025.117313_b0590","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/annonc\/mdm204","article-title":"A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors","volume":"18","author":"Candelaria","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2025.117313_b0595","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1002\/jcb.26407","article-title":"Procaine is a specific DNA methylation inhibitor with anti-tumor effect for human gastric cancer","volume":"119","author":"Li","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bcp.2025.117313_b0600","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13072-021-00429-0","article-title":"The DNMT1 inhibitorGSK-3484862 mediates global demethylation in murine embryonic stem cells","volume":"14","author":"Azevedo Portilho","year":"2021","journal-title":"Epigenetics Chromatin"},{"key":"10.1016\/j.bcp.2025.117313_b0605","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcaf018","article-title":"GSK-3484862, a DNMT1 degrader, promotes DNMT3B expression in lung cancer cells","author":"Chen","year":"2025","journal-title":"NAR Cancer 7"},{"key":"10.1016\/j.bcp.2025.117313_b0610","doi-asserted-by":"crossref","unstructured":"Q. Chen, B. Liu, Y. Zeng, J.W. Hwang, N. Dai, I.R. Corr\u00eaa, M.R. Estecio, X. Zhang, M.A. Santos, T. Chen, X. Cheng, GSK-3484862 targets DNMT1 for degradation in cells, NAR Cancer 5 (2023) zcad022. https:\/\/doi.org\/10.1093\/narcan\/zcad022.","DOI":"10.1093\/narcan\/zcad022"},{"key":"10.1016\/j.bcp.2025.117313_b0615","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/jcb.22998","article-title":"Usp7 and Uhrf1 control ubiquitination and stability of the maintenance DNA methyltransferase Dnmt1","volume":"112","author":"Qin","year":"2011","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bcp.2025.117313_b0620","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/s43018-021-00249-x","article-title":"Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia","volume":"2","author":"Pappalardi","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.bcp.2025.117313_b0625","doi-asserted-by":"crossref","first-page":"992","DOI":"10.3389\/fphar.2020.00992","article-title":"Natural Products Impacting DNA Methyltransferases and Histone Deacetylases","volume":"11","author":"Akone","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117313_b0630","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062152","article-title":"Molecular Modeling Studies of the Novel Inhibitors of DNA Methyltransferases SGI-1027 and CBC12: Implications for the Mechanism of Inhibition of DNMTs","volume":"8","author":"Yoo","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2025.117313_b0635","doi-asserted-by":"crossref","first-page":"9055","DOI":"10.1073\/pnas.1019629108","article-title":"Structural insight into maintenance methylation by mouse DNA methyltransferase 1 (Dnmt1)","volume":"108","author":"Takeshita","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bcp.2025.117313_b0640","doi-asserted-by":"crossref","first-page":"15344","DOI":"10.1074\/jbc.M110.209882","article-title":"The Replication Focus Targeting Sequence (RFTS) Domain is a DNA-competitive Inhibitor of Dnmt1","volume":"286","author":"Syeda","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2025.117313_b0645","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1093\/nar\/gkq187","article-title":"Targeting of 5-aza-2\u2032-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme","volume":"38","author":"Patel","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bcp.2025.117313_b0650","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1038\/onc.2012.9","article-title":"5-Aza-2\u2032-deoxycytidine-induced genome rearrangements are mediated by DNMT1","volume":"31","author":"Maslov","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2025.117313_b0655","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1158\/0008-5472.CAN-04-2957","article-title":"Epigenetic Reactivation of Tumor Suppressor Genes by a Novel Small-Molecule Inhibitor of Human DNA Methyltransferases","volume":"65","author":"Brueckner","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2025.117313_b0660","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1158\/0008-5472.CAN-08-3669","article-title":"A New Class of Quinoline-based DNA Hypomethylating Agents Reactivates Tumor Suppressor Genes by Blocking DNA Methyltransferase 1 activity and Inducing its Degradation","volume":"69","author":"Datta","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2025.117313_b0665","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/febs.15750","article-title":"Clinical advances in targeting epigenetics for cancer therapy","volume":"289","author":"Feng","year":"2022","journal-title":"FEBS J."},{"key":"10.1016\/j.bcp.2025.117313_b0670","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S1470-2045(15)00038-8","article-title":"Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study","volume":"16","author":"Issa","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2025.117313_b0675","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12865-020-0337-5","article-title":"The DNA methyltransferase inhibitor, guadecitabine, targets tumor-induced myelopoiesis and recovers T cell activity to slow tumor growth in combination with adoptive immunotherapy in a mouse model of breast cancer","volume":"21","author":"Luker","year":"2020","journal-title":"BMC Immunol."},{"key":"10.1016\/j.bcp.2025.117313_b0680","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/bloodadvances.2024012569","article-title":"Survival for the fittest: guadecitabine in rel\/ref AML","volume":"8","author":"Sheehy","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.bcp.2025.117313_b0685","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13046-025-03294-x","article-title":"Stochastic demethylation and redundant epigenetic suppressive mechanisms generate highly heterogeneous responses to pharmacological DNA methyltransferase inhibition","volume":"44","author":"Jakobsen","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2025.117313_b0690","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41392-022-00896-1","article-title":"The DNMT1-PAS1-PH20 axis drives breast cancer growth and metastasis","volume":"7","author":"Fu","year":"2022","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.bcp.2025.117313_b0695","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.3390\/molecules19033149","article-title":"5-Azacytidine Induces Anoikis, Inhibits Mammosphere Formation and Reduces Metalloproteinase 9 activity in MCF-7 Human Breast Cancer Cells","volume":"19","author":"Chang","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2025.117313_b0700","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s10549-009-0420-3","article-title":"Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells","volume":"120","author":"Billam","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bcp.2025.117313_b0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116324","article-title":"Discovery of the first chemical tools to regulate MKK3-mediated MYC activation in cancer","volume":"45","author":"Yang","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117313_b0710","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41420-024-01895-7","article-title":"Dual inhibitors of DNMT and HDAC induce viral mimicry to induce antitumour immunity in breast cancer","volume":"10","author":"Huang","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.bcp.2025.117313_b0715","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1158\/0008-5472.CAN-15-2249","article-title":"Combined Inhibition of DNMT and HDAC Blocks the Tumorigenicity of Cancer Stem-like Cells and Attenuates Mammary Tumor Growth","volume":"76","author":"Pathania","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2025.117313_b0720","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1475-2867-6-2","article-title":"Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines","volume":"6","author":"Chavez-Blanco","year":"2006","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bcp.2025.117313_b0725","doi-asserted-by":"crossref","first-page":"8823","DOI":"10.2147\/OTT.S187306","article-title":"Antimetastatic effect of epigenetic drugs, hydralazine and valproic acid, in Ras-transformed NIH 3T3 cells","volume":"11","author":"P\u00e9rez-C\u00e1rdenas","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.bcp.2025.117313_b0730","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-18-0204","article-title":"An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations","volume":"24","author":"Pulliam","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2025.117313_b0735","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13058-024-01954-y","article-title":"Low dose DNA methyltransferase inhibitors potentiate PARP inhibitors in homologous recombination repair deficient tumors","volume":"27","author":"Pacaud","year":"2025","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bcp.2025.117313_b0740","doi-asserted-by":"crossref","unstructured":"Y.-H. Chu, Y.-C. Huang, P.-Y. Chiu, W.-H. Kuo, Y.-R. Pan, Y.-T. Kuo, R.-H. Wang, Y.-C. Kao, Y.-H. Wang, Y.-F. Lin, K.-T. Lin, Combating breast cancer progression through combination therapy with hypomethylating agent and glucocorticoid, iScience 26 (2023) 106597. https:\/\/doi.org\/10.1016\/j.isci.2023.106597.","DOI":"10.1016\/j.isci.2023.106597"},{"key":"10.1016\/j.bcp.2025.117313_b0745","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1093\/carcin\/bgt284","article-title":"Synergistic anti-breast cancer effect of a combined treatment with the methyl donor S -adenosyl methionine and the DNA methylation inhibitor 5-aza-2\u2032-deoxycytidine","volume":"35","author":"Chik","year":"2014","journal-title":"CARCIN"},{"key":"10.1016\/j.bcp.2025.117313_b0750","doi-asserted-by":"crossref","first-page":"10322","DOI":"10.1111\/jcmm.15642","article-title":"S\u2010adenosylmethionine in combination with decitabine shows enhanced anti\u2010cancer effects in repressing breast cancer growth and metastasis","volume":"24","author":"Mahmood","year":"2020","journal-title":"J Cellular Molecular Medi"},{"key":"10.1016\/j.bcp.2025.117313_b0755","doi-asserted-by":"crossref","first-page":"626","DOI":"10.18632\/oncotarget.27922","article-title":"Inhibition of resistant triple-negative breast cancer cells with low-dose 6-mercaptopurine and 5-azacitidine","volume":"12","author":"Singh","year":"2021","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2025.117313_b0760","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0043671","article-title":"ING1 and 5-Azacytidine Act Synergistically to Block Breast Cancer Cell Growth","volume":"7","author":"Thakur","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2025.117313_b0765","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1188087","article-title":"Combination of verteporfin-photodynamic therapy with 5-aza-2\u2019-deoxycytidine enhances the anti-tumour immune response in triple negative breast cancer","volume":"14","author":"Banerjee","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2025.117313_b0770","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10549-014-2857-2","article-title":"A combination treatment with DNA methyltransferase inhibitors and suramin decreases invasiveness of breast cancer cells","volume":"144","author":"Borges","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bcp.2025.117313_b0775","article-title":"Pyroptosis\u2010Inducing Platinum(IV) Prodrugs via GSDME Pathway for Chemoimmunotherapy and Metastasis Inhibition in Triple\u2010Negative Breast Cancer","volume":"12","author":"Yang","year":"2025","journal-title":"Adv Sci (weinh)"},{"key":"10.1016\/j.bcp.2025.117313_b0780","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.yexmp.2011.09.007","article-title":"Combination of thiazolidinedione and hydralazine suppresses proliferation and induces apoptosis by PPAR\u03b3 up-expression in MDA-MB-231 cells","volume":"91","author":"Jiang","year":"2011","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.bcp.2025.117313_b0785","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.21873\/anticanres.11573","article-title":"Azacytidine-induced Chemosensitivity to Doxorubicin in Human Breast Cancer MCF7 Cells","volume":"37","author":"Khan","year":"2017","journal-title":"AR"},{"key":"10.1016\/j.bcp.2025.117313_b0790","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3390\/cancers14010248","article-title":"Epigenetic Priming with Decitabine Augments the Therapeutic effect of Cisplatin on Triple-negative Breast Cancer Cells through Induction of Proapoptotic factor NOXA","volume":"14","author":"Nakajima","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.bcp.2025.117313_b0795","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11010-010-0473-y","article-title":"Demethylating agent 5-aza-2-deoxycytidine enhances susceptibility of breast cancer cells to anticancer agents","volume":"342","author":"Mirza","year":"2010","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.bcp.2025.117313_b0800","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejps.2018.07.028","article-title":"Reversal of epigenetic aberrations associated with the acquisition of doxorubicin resistance restores drug sensitivity in breast cancer cells","volume":"123","author":"Ponnusamy","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bcp.2025.117313_b0805","doi-asserted-by":"crossref","DOI":"10.1177\/15330338241260658","article-title":"Systematic Characterization of DNA Methyltransferases Family in Tumor Progression and Antitumor Immunity","volume":"23","author":"Huang","year":"2024","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.bcp.2025.117313_b0810","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/1476-4598-9-305","article-title":"Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation","volume":"9","author":"Gravina","year":"2010","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bcp.2025.117313_b0815","doi-asserted-by":"crossref","first-page":"4724","DOI":"10.1038\/s41467-023-40389-5","article-title":"A multiplex blood-based assay targeting DNA methylation in PBMCs enables early detection of breast cancer","volume":"14","author":"Wang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2025.117313_b0820","doi-asserted-by":"crossref","first-page":"e1423","DOI":"10.1002\/ctm2.1423","article-title":"Targeted demethylation of the CDO1 promoter based on CRISPR system inhibits the malignant potential of breast cancer cells","volume":"13","author":"Yang","year":"2023","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.bcp.2025.117313_b0825","doi-asserted-by":"crossref","first-page":"12660","DOI":"10.3390\/ijms241612660","article-title":"Methylation Profile of Small Breast Cancer Tumors Evaluated by Modified MS-HRM","volume":"24","author":"Krasnyi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.117313_b0830","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.31557\/APJCP.2023.24.12.4035","article-title":"E74-like factor 5 Promoter Methylation in Circulating Tumor DNA as a potential Prognostic Marker in Breast Cancer patients","volume":"24","author":"Salimi","year":"2023","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.bcp.2025.117313_b0835","first-page":"108","article-title":"Study of DACH1 Expression and its Epigenetic regulators as possible Breast Cancer-Related Biomarkers, Avicenna J Med","volume":"15","author":"Nasirpour","year":"2023","journal-title":"Biotechnol"},{"key":"10.1016\/j.bcp.2025.117313_b0840","article-title":"Septin9 DNA methylation is associated with breast cancer recurrence or metastasis","volume":"52","author":"Zhang","year":"2024","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.bcp.2025.117313_b0845","unstructured":"J. Sparano, Phase I-II Trial of Vorinostat Plus Weekly Paclitaxel (+/- Trastuzumab) Followed by Doxorubicin-cyclophosphamide in Patients With Locally Advanced Breast Cancer, clinicaltrials.gov, 2020. https:\/\/clinicaltrials.gov\/study\/NCT00574587 (accessed August 27, 2025)."},{"key":"10.1016\/j.bcp.2025.117313_b0850","unstructured":"National Cancer Institute (NCI), Phase II Study of Azacitidine and Entinostat (SNDX-275) in Patients With Advanced Breast Cancer, clinicaltrials.gov, 2025. https:\/\/clinicaltrials.gov\/study\/NCT01349959 (accessed August 27, 2025)."},{"key":"10.1016\/j.bcp.2025.117313_b0855","unstructured":"University of Southern California, A Pilot Clinical Trial to Evaluate the Biological Activity of 5-azacitidine on ER and PR Expression in Triple Negative Invasive Breast Cancer, clinicaltrials.gov, 2014. https:\/\/clinicaltrials.gov\/study\/NCT01292083 (accessed August 27, 2025)."},{"key":"10.1016\/j.bcp.2025.117313_b0860","unstructured":"Celgene, Expanded Access for CC-486, clinicaltrials.gov, 2020. https:\/\/clinicaltrials.gov\/study\/NCT03723135 (accessed August 27, 2025)."},{"key":"10.1016\/j.bcp.2025.117313_b0865","unstructured":"K. Shen, Decitabine Plus Carboplatin in the Treatment of Metastatic Triple Negative Breast Cancer, clinicaltrials.gov, 2022. https:\/\/clinicaltrials.gov\/study\/NCT03295552 (accessed August 27, 2025)."},{"key":"10.1016\/j.bcp.2025.117313_b0870","unstructured":"R. O'Regan, Phase I/II Trial of Tamoxifen Following Epigenetic Regeneration of Estrogen Receptor Using Decitabine and LBH 589 in Patients With Triple Negative Metastatic Breast Cancer, clinicaltrials.gov, 2015. https:\/\/clinicaltrials.gov\/study\/NCT01194908 (accessed August 27, 2025)."},{"key":"10.1016\/j.bcp.2025.117313_b0875","unstructured":"J. Doroshow, A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU), clinicaltrials.gov, 2019. https:\/\/clinicaltrials.gov\/study\/NCT00978250 (accessed August 27, 2025)."},{"key":"10.1016\/j.bcp.2025.117313_b0880","unstructured":"P. Choyke, Phase 0 Trial of [F-18]-5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine, clinicaltrials.gov, 2020. https:\/\/clinicaltrials.gov\/study\/NCT01479348 (accessed August 27, 2025)."},{"key":"10.1016\/j.bcp.2025.117313_b0885","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/1535-7163.MCT-11-0458","article-title":"DNA Methyltransferase Inhibitor, Zebularine, Delays Tumor Growth and Induces Apoptosis in a Genetically Engineered Mouse Model of Breast Cancer","volume":"11","author":"Chen","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2025.117313_b0890","doi-asserted-by":"crossref","first-page":"6400","DOI":"10.1158\/0008-5472.CAN-07-0251","article-title":"Delivery of 5-Aza-2\u2032-Deoxycytidine to Cells using Oligodeoxynucleotides","volume":"67","author":"Yoo","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2025.117313_b0895","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.canlet.2008.02.069","article-title":"2\u2032-Deoxy-N4-[2-(4-nitrophenyl)ethoxycarbonyl]-5-azacytidine: a novel inhibitor of DNA methyltransferase that requires activation by human carboxylesterase 1","volume":"266","author":"Byun","year":"2008","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2025.117313_b0900","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.yexmp.2012.10.004","article-title":"DNA methyltransferase 1 is essential for initiation of the colon cancers","volume":"94","author":"Morita","year":"2013","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.bcp.2025.117313_b0905","unstructured":"National Institute of Cancerolog\u00eda, A Phase II Clinical Study of Hydralazine and Valproic Acid in Combination With Neoadjuvant Cytotoxic Chemotherapy in Stage IIB and IIIA Breast Carcinoma, clinicaltrials.gov, 2006. https:\/\/clinicaltrials.gov\/study\/NCT00395655 (accessed August 27, 2025)."},{"key":"10.1016\/j.bcp.2025.117313_b0910","unstructured":"ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/study\/NCT00575978?cond=NCT00575978&rank=1 (accessed August 27, 2025)."},{"key":"10.1016\/j.bcp.2025.117313_b0915","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1038\/s41467-020-17537-2","article-title":"Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers","volume":"11","author":"Glodzik","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2025.117313_b0920","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.breast.2022.08.012","article-title":"A systematic review and meta-analysis of BRCA1\/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer","volume":"66","author":"Jia","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.bcp.2025.117313_b0925","article-title":"BRCA1 Promoter Methylation Status in 1031 Primary Breast Cancers Predicts favorable Outcomes following Chemotherapy","author":"Stefansson","year":"2019","journal-title":"JNCI Cancer Spectr 4"},{"key":"10.1016\/j.bcp.2025.117313_b0930","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1349-7006.2010.01840.x","article-title":"Secondary mutations of BRCA1\/2 and drug resistance","volume":"102","author":"Dhillon","year":"2011","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bcp.2025.117313_b0935","doi-asserted-by":"crossref","first-page":"87151","DOI":"10.18632\/oncotarget.19895","article-title":"The role of BRCA status on prognosis in patients with triple-negative breast cancer","volume":"8","author":"Xie","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2025.117313_b0940","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1133472","article-title":"Targeting the BRCA1\/2 deficient cancer with PARP inhibitors: Clinical outcomes and mechanistic insights","volume":"11","author":"Ragupathi","year":"2023","journal-title":"Front. Cell Dev. Biol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225005787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225005787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T05:25:00Z","timestamp":1761456300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225005787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":188,"alternative-id":["S0006295225005787"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117313","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DNA methylation as an oncogenic driver in breast cancer: Therapeutic targeting via epigenetic reprogramming of DNA methyltransferases","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117313","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117313"}}